<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877979</url>
  </required_header>
  <id_info>
    <org_study_id>IPM 042</org_study_id>
    <nct_id>NCT02877979</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety &amp; Assess Local and Systemic PK of DS003 Vaginal Tablets Administered to Healthy HIV-negative Women</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Dose Escalation Trial to Evaluate the Safety and to Assess Local and Systemic Pharmacokinetics of DS003 Vaginal Tablets Administered to Healthy HIV-negative Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomised, placebo-controlled, dose escalation trial to evaluate the safety
      and to assess local and systemic pharmacokinetics of ds003 vaginal tablets administered to
      healthy HIV-negative women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2015</start_date>
  <completion_date type="Actual">August 26, 2016</completion_date>
  <primary_completion_date type="Actual">August 26, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of three escalating doses of DS003 (1 mg, 3 mg and 10 mg), administered in a vaginal tablet formulation, to healthy, HIV-negative female volunteers.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Gynaecological assessments, including pelvic examination and colposcopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the local (vaginal fluids) and systemic (plasma) DS003 PK profile and the 24 hour cervical tissue concentration when administered in three escalating doses of a vaginal tablet formulation.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurement of DS003 concentrations in plasma, vaginal fluids and cervical tissue collected at various time points after administration of the vaginal tablet(s).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>DS003 vaginal tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS003 vaginal tablet</intervention_name>
    <description>The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.</description>
    <arm_group_label>DS003 vaginal tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women must meet all of the following criteria to be eligible for enrolment:

          1. Women ≥ 18 and ≤ 45 years of age who can give written informed consent

          2. BMI of ≥ 18 and &lt; 30 kg/m2

          3. Vital signs within normal limits and no clinically significant ECG findings

          4. Available for all visits and consent to follow all procedures scheduled for the trial

          5. Healthy, based on medical history, vital signs, physical examination, urinalysis
             (dipstick and microscopy), laboratory evaluations for genital infections (bacterial
             vaginosis, gonorrhoea, chlamydia and trichomonas) and laboratory evaluations for
             haematology and biochemistry

          6. HIV-negative as determined by an HIV test at the time of screening

          7. On a stable form of contraception, defined as:

               -  A stable oral contraceptive regimen for at least 2 months prior to enrolment, OR

               -  Transdermal contraceptive patch for at least 3 months prior to enrolment, OR

               -  Subcutaneous implant inserted at least 3 months prior to enrolment, OR

               -  Long-acting progestins for at least 2 consecutive injections, OR An IUD inserted
                  (with no vaginal or gynaecological complaints associated with its use) at least 3
                  months prior to enrolment, OR

               -  Have undergone surgical sterilisation at least 3 months prior to enrolment AND be
                  willing to use oral contraceptives if necessary to delay menstruation while
                  taking part in the trial

          8. Upon pelvic examination and colposcopy at screening and visual inspection of the
             cervix at the time of enrolment, the cervix and vagina appear normal as determined by
             the Investigator

          9. Asymptomatic for urogenital infections at the time of screening (if a woman is
             diagnosed with any curable STI, either clinically or by laboratory test at the time of
             screening, she must complete the full course of treatment and have a healthy genital
             tract before being considered for potential re-screening)

         10. Willing to refrain from the use of topical vaginal medications, vaginal products or
             objects, including tampons, female condoms, cotton wool, rags, diaphragms, cervical
             caps (or any other vaginal barrier method), douches, lubricants, vibrators/dildos, and
             drying agents for 7 days prior to enrolment and for the duration of the trial

         11. Documentation of no abnormality on cervical cytology, including grossly bloody smear,
             within 90 days prior to screening

         12. Willing to refrain from participation in any other research trial for the duration of
             this trial

         13. Willing to provide adequate locator information for trial retention purposes and be
             reachable per local standard procedures, e.g. by home visit or telephone, or via
             family or close neighbour contacts (confidentiality to be maintained)

         14. Willing to agree to abstain from all the following for a total of 2 days (48 hours)
             prior to each trial visit, and for a total of 3 days (72 hours) after the biopsy
             procedure:

             Penile-vaginal intercourse

             • Oral contact with her genitalia

         15. Hepatitis B and C negative at the time of screening

        Exclusion Criteria:

        Women who meet any of the exclusion criteria below are not eligible:

          1. Currently pregnant or had their last pregnancy outcome within 3 months prior to
             screening

          2. Currently breast-feeding

          3. Currently or within 2 months of participation in any other clinical research trial
             involving investigational or marketed products prior to screening

          4. Untreated symptomatic urogenital infections, e.g. urinary tract or other sexually
             transmitted infections, or other gynaecological conditions such as vaginal itching,
             pain, or discharge, prior to enrolment

          5. Have a Grade 2 or higher pelvic examination finding, according to the DAIDS Table for
             Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital
             Grading Table for Use in Microbicide Studies

          6. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,
             urethral obstruction, incontinence or urge incontinence

          7. Current vulvar or vaginal symptoms/abnormalities that could influence the trial
             results

          8. Cervical cytology at screening that requires cryotherapy, biopsy, treatment, or
             further evaluation

          9. Symptomatic genital herpes simplex virus (HSV) infection or a history of genital
             herpetic infection

         10. Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at
             baseline (screening) according to the current version of the DAIDS Table for Grading
             the Severity of Adult and Pediatric Adverse Events

         11. Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or
             gynaecologic surgery within 90 days prior to enrolment

         12. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of
             sensitivity/allergy to latex

         13. Any serious acute, chronic or progressive disease (e.g. any known history of neoplasm,
             cancer, diabetes, epilepsy, cardiac disease, autoimmune disease, HIV, AIDS, or blood
             dyscrasias), or signs of cardiac disease, renal failure, or severe malnutrition

         14. Have undergone a hysterectomy

         15. History of drug or substance abuse within 1 year of enrolment

         16. Use of tobacco within 6 months of enrolment

         17. Not willing to abstain from alcohol from 14 days prior to enrolment until completion
             of trial participation

         18. Have had significant blood loss, or have donated or received one or more units of
             blood within 6 weeks prior to enrolment

         19. Have a positive urine drug or positive breath alcohol screen at screening or enrolment

         20. Any disease or condition (medical or surgical) that might compromise haematological,
             cardiovascular, pulmonary, renal, gastrointestinal, or central nervous system
             function; or any other conditions that might interfere with the absorption,
             distribution, metabolism, or excretion of the investigational product, or that would
             place the participant at increased risk, as determined by the Investigator

         21. Regular use of, or have received, any concomitant prescription, over-the-counter, or
             herbal medications or nutritional supplements within 14 days prior to enrolment

         22. Any condition(s) that, in the opinion of the Investigator, might interfere with
             adherence to trial requirements or evaluation of the trial objectives
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

